Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
Open Access
- 13 July 2016
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 12258
Abstract
The JAK/STAT pathway is an attractive target for breast cancer therapy due to its frequent activation, and clinical trials evaluating JAK inhibitors (JAKi) in advanced breast cancer are ongoing. Using patient biopsies and preclinical models of breast cancer, we demonstrate that the JAK/STAT pathway is active in metastasis. Unexpectedly, blocking the pathway with JAKi enhances the metastatic burden in experimental and orthotopic models of breast cancer metastasis. We demonstrate that this prometastatic effect is due to the immunosuppressive activity of JAKi with ensuing impairment of NK-cell-mediated anti-tumour immunity. Furthermore, we show that immunostimulation with IL-15 overcomes the enhancing effect of JAKi on metastasis formation. Our findings highlight the importance of evaluating the effect of targeted therapy on the tumour environment. The impact of JAKi on NK cells and the potential value of immunostimulators to overcome the weakened tumour immunosurveillance, are worthwhile considering in the clinical setting of breast cancer.Keywords
This publication has 70 references indexed in Scilit:
- JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasmsBritish Journal of Haematology, 2015
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patientsAnnals of Oncology, 2014
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?Blood, 2013
- The hard factsNature, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse modelsProceedings of the National Academy of Sciences, 2010
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Developmental pathways that generate natural-killer-cell diversity in mice and humansNature Reviews Immunology, 2007
- Activation of NK cell cytotoxicityMolecular Immunology, 2005
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003